HA, a negatively charged linear polysaccharide, was integrated into the formulation to enhance colloidal stability of PCNs and provide active tumor-targeting capabilities through specific binding to CD44, a receptor overexpressed in many cancer types, including colon cancer [26,27]. Here, CD44 is linked to cancer.